In this paper we determine the ability of a new multivalentvaccine, comprising core canine viral and four leptospira serovarsvaccine antigens, and containing a canine parvovirus type 2b strainto induce cross-neutralising antibody responses to CPV-2, CPV-2aand CPV-2c.